Devices & Diagnostics

Gilead is using iRhythm patch to test heartbeat irregularities – pharma and wearables unite

Gilead Sciences has started a Phase II/III trial of its novel cardiac patch worn to monitor changes in arrhythmia.


Biopharmas are looking to incorporate wearables when it comes to patient monitoring within clinical trials. Questions about how this data will or should be used still remain for regulators.

But Gilead Sciences has started a Phase II/III trial of its novel hypertrophic cardiomyopathy candidate eleclazine that incorporates the iRhythm ZIO Patch to measure an exploratory endpoint (a patch worn to monitory changes in arrhythmia).

The patch monitors things like premature ventricular complexes, non-sustained ventricular tachycardia and paroxysmal atrial fibrillation – the goal is to catch hypertrophic cardiomyopathy (HCM) quick. This is the most common cardiac disorder, but it is commonly not diagnosed, and there is not approved treatment currently.

The current Gilead study is called LIBERTY-HCM. A 180-patient study started in February and is designed to test iRhythm’s ZIO Service.

The ongoing Gilead eleclazine study is called LIBERTY-HCM; as part of the study patients will receive “periodic arrhythmic burden assessments using iRhythm’s ZIO Service to determine if the investigational treatment improves symptoms such as AFib in patients with symptomatic HCM,” according to iRhythm. This is the first study of its kind for looking how to optimize treatment for HCM.

The iRhythm patch is also in a massive up to 6,100 patient trial by the Scripps Translational Science Institute (STSI) to identify asymptomatic atrial fibrillation (AFib) patients that launched late last year.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Photos: Flickr user aussiegall, iRhythm